

馬文哲博士



教授
中藥質量研究國家重點實驗室
澳門科技大學
地址：澳門氹仔偉龍馬路 I 座 I01-115 室
電話：+853-88972462
傳真：+853-28825886
電郵：wzma@must.edu.mo

2005年博士畢業于中國科學院上海藥物研究所，隨後在美國國立衛生研究院（NIH）進行博士後研究及工作。2012年入職澳門科技大學中藥質量研究國家重點實驗室，現為教授，項目負責人。馬文哲博士主要從事線粒體代謝與腫瘤發生和治療及抗腫瘤天然產物的發現及機理研究，第一或通訊作者文章發表在 New England Journal of Medicine、Nature Communications、Free Radical Biology and Medicine、Pharmacological Research、EBioMedicine、Phytomedicine、Acta Pharmacologica Sinica、Drug Discovery Today、Antioxidants、British Journal of Pharmacology等雜誌上；主持澳門科技發展基金項目7項；第一發明人獲授權4項澳大利亞專利、2項美國專利及3項中國專利；參編國家衛生和計劃生育委員會“十三五”規劃教材《分子毒理學》。

研究方向：

- 線粒體代謝與腫瘤發生和治療
- 抗腫瘤天然產物的發現及機理研究

學歷：

2002-2005	理學博士	藥理學	中國科學院上海藥物研究所
1999-2002	理學碩士	微生物與生化藥學	中國藥科大學
1995-1999	工學學士	微生物製藥	中國藥科大學

專業經歷：

2025/07-至今	教授	澳門科技大學
2018/07-2025/06	副教授	澳門科技大學
2012/08-2018/06	助理教授	澳門科技大學
2007/08-2012/07	研究專員	美國國立衛生研究院
2006/01-2007/07	博士後	美國國立衛生研究院

科研項目（項目負責人）：

1. 2025/03-2028/03，澳門科學技術發展基金，0075/2024/RIB2，基于CRISPR技術的中藥核酸現場檢測平臺的研發
2. 2023/01-2026/01，澳門科學技術發展基金，0105/2022/A2，7-氮雜吡啶衍生物DA-5誘導細胞鐵死亡抗三陰性乳腺癌
3. 2021/01-2023/12，五邑大學港澳聯合研發基金，2019WGALH12，PARP抑制劑抗帕金森病的作用及機制研究
4. 2020/09-2023/09，澳門科學技術發展基金，0036/2020/A1，他汀類藥物預防Li-Fraumeni綜合症腫瘤生成的作用與機制研究
5. 2020/04-2021/08，澳門科學技術發展基金，0039/2020/A，新型冠狀病毒床旁即時核算診斷試劑的研發及應用
6. 2019/06-2022/06，澳門科學技術發展基金，0013/2019/A1，新型IDH1突變抑制劑WM17和APTM靶向治療腦膠質瘤的作用與機制研究
7. 2016/02-2019/02，澳門科學技術發展基金，034/2015/A1，葡萄糖代謝調節劑的篩選及抗腫瘤研究
8. 2013/11-2016/05，澳門科學技術發展基金，088/2012/A3，PCR陣列在新丹參內酯抗乳腺癌作用機理研究及相同機理藥物篩選中的應用
9. 2012/11-2013/11，澳門科技大學研究基金（普通研究項目），0270，用于抗腫瘤中藥作用機理研究的PCR陣列的建立及應用

專利（第一發明人）：

1. 川貝母和平貝母的檢測區分方法、裝置及終端設備，2024.07.30，CN118406796 A
2. 一種丁烯內酯類化合物及其製備方法和應用，2024.01.02，CN117327036 A
3. 表小檗碱的新用途，2023.09.26，CN 116803390 A
4. 3,5-二取代-7氮雜吡啶衍生物及其合成方法與應用，2024. 04. 02，CN 115057856 B
5. 一種聯二厚樸脂素及其製備方法和應用，2024. 04. 02，CN 115466237 B
6. 茵梔黃製劑在製備治療腫瘤的藥物中的應用，2024. 05. 31，CN 116370535 B
7. Method for treating cancer, 2018. 01. 31, Australia, 2018100066
8. Method of treating breast cancer, 2018. 01. 03, Australia, 2017101728
9. Use of nobiletin in cancer treatment, 2017. 11. 07, United States Patent, US 9,808,477 B2
10. Use of tangeretin in cancer treatment, 2017. 11. 07, United States Patent, US 9,808,439 B2
11. Use of nobiletin in cancer treatment, 2015. 10. 08, Australia, 2015101287
12. Use of tangeretin in cancer treatment, 2015. 10. 08, Australia, 2015101288

教材：

1. 《分子毒理學》，章節編者，國家衛生和計劃生育委員會“十三五”規劃教材，人民衛生出版社，2017年第1版，2021年第2版

通訊/第一作者文章：

1. Whether aristolochic acid directly drives hepatocarcinogenesis: comprehensive investigations from mutational signatures to animal models, *Arch Toxicol*, 2025. 10.1007/s00204-025-04087-z
2. Discovery of Bi-magnolignan as a Novel BRD4 Inhibitor Inducing Apoptosis and DNA Damage for Cancer Therapy, *Biochem Pharmacol*, 2025. 10.1016/j.bcp.2025.116843: 116843.
3. Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53, *Front Pharmacol*, 2025. 16: 1492305.
4. Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF- κ B/NLRP3 signaling pathway. *J Tradit Complement Med*, 2025. 10.1016/j.jtcme.2025.03.001.
5. Xanthocillin X Dimethyl Ether Exhibits Anti-Proliferative Effect on Triple-Negative Breast Cancer by Depletion of Mitochondrial Heme. *Marine Drugs*, 2025. 23(4): 146.
6. Construction of a prognostic risk model for clear cell renal cell carcinomas based on centrosome amplification-related genes. *Mol Genet Genomics*, 2025. 300(1): 30.
7. Dental pulp stem cells derived exosomes inhibit ferroptosis via regulating the Nrf2-keap1/GPX4 signaling pathway to ameliorate chronic kidney disease injury. *Tissue Cell*, 2025. 93: 102670.
8. Tanshinlactone triggers methuosis in breast cancer cells via NRF2 activation, *Front Pharmacol*, 2025. 15: 1534217.
9. NGR1 Mitigates Neuronal Apoptosis Mediated by ITGA11 Following Subarachnoid Hemorrhage, *Mol Med Rep*, 2025. 31(3) : 67
10. Yunnan Baiyao exerts anti-glioma activity by inducing autophagy-dependent necroptosis. *J Ethnopharmacol*, 2024. 10.1016/j.jep.2024.118658: 118658.
11. Species discrimination of Fritillaria Bulbus using PCR-CRISPR/ Cas12a-based nucleic acid detection. *J Appl Res Med Aromat Plants*, 2024. 43.
12. Comparison of (68)Ga-FAP-2286 and (18)F-FDG PET/CT in the diagnosis of advanced lung cancer. *Front Oncol*, 2024. 14: 1413771.
13. A chalcone derivative SBD-2 exerts anticancer effects in human colorectal cancer cells. *Futur J Pharm Sci*, 2024. 10(1).
14. A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma. *Front Oncol*, 2024. 14: 1344643.
15. Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. *Br J Pharmacol*, 2024. 10.1111/bph.16489.

16. Prospective comparison of (68)Ga-DOTA-ibandronate and bone scans for detecting bone metastases in breast cancer. *Front Oncol*, 2024. 14: 1428498.
17. Notopterygium Incisum Extract Promotes Apoptosis by Preventing the Degradation of BIM in Colorectal Cancer. *Curr Med Sci*, 2024. 10.1007/s11596-024-2883-1.
18. Lactic acid: a narrative review of a promoter of the liver cancer microenvironment. *J Gastrointest Oncol*, 2024. 15(3): 1282-1296.
19. Transcriptome sequencing and metabolome analysis reveal the molecular mechanism of *Salvia miltiorrhiza* in response to drought stress. *BMC Plant Biol*, 2024. 24(1): 446.
20. Single-cell profiling reveals the metastasis-associated immune signature of hepatocellular carcinoma. *Immun Inflamm Dis*, 2024. 12(5): e1264.
21. Four sulfur-containing compounds with effect from marine-derived fungus *aspergillus terreus*. *Fitoterapia*, 2024. 10.1016/j.fitote.2024.105967: 105967.
22. Epiberberine inhibits bone metastatic breast cancer-induced osteolysis. *J Ethnopharmacol*, 2024. 10.1016/j.jep.2024.118039: 118039.
23. Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis. *Front Cell Infect Microbiol*, 2024. 14: 1358063.
24. Involucrasin B Inhibits the Proliferation of Caco-2 Cells by Regulating the TGF β /SMAD2-3-4 Pathway. *Molecules*, 2024. 29(3).
25. Phloretic acid requires the insulin/IGF-1 pathway and autophagy to enhance stress resistance and extend the lifespan of *Caenorhabditis elegans*. *Front Pharmacol*, 2024. 15: 1384227.
26. Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics. *Drug Discov Today*, 2024. 10.1016/j.drudis.2024.104026: 104026.
27. Lovastatin-Induced Mitochondrial Oxidative Stress Leads to the Release of mtDNA to Promote Apoptosis by Activating cGAS-STING Pathway in Human Colorectal Cancer Cells. *Antioxidants (Basel)*, 2024. 13(6).
28. Berberine targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia with IDH1 mutation. *Chin J Nat Med*, 2023. 21(2): 136-145.
29. Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway. *Oncol Lett*, 2023. 25(6): 218.
30. Yinzhihuang injection induces apoptosis and suppresses tumor growth in acute myeloid leukemia cells. *PLoS One*, 2023. 18(10): e0289697.
31. Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy. *Cancers*, 2022, 14(23): 5758
32. Network pharmacology-based investigation and experimental validation of the mechanism of scutellarin in the treatment of acute myeloid leukemia. *Front Pharmacol*, 2022, 13: 952677

33. Hinokiflavone induces apoptosis, cell cycle arrest and autophagy in chronic myeloid leukemia cells through MAPK/NF- κ B signaling pathway. *BMC Complementary Medicine and Therapies*, 2022, 22(1):100
34. Mitochondrial toxicity evaluation of traditional Chinese medicine injections with a dual in vitro approach. *Front Pharmacol*, 2022, 13: 1039235
35. dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation. *Virus Research*, 2021, 34: 198530
36. Hirsutanol A inhibits T-acute lymphocytic leukemia Jurkat cell viability through cell cycle arrest and p53-dependent induction of apoptosis. *Exp Ther Med*, 2021. 22(1): 741.
37. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment. *Biochem Biophys Res Commun*, 2021. 551: 38-45.
38. High expression of HOXA5 is associated with poor prognosis in acute myeloid leukemia. *Curr Probl Cancer*, 2021. 45(3): 100673.
39. Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin. *Acta Pharmacologica Sinica*, 2021, 42: 1875–1887
40. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells. *Phytomedicine*, 2021, 153551
41. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 27 RCTs. *Phytomedicine*, 2020, 67:153154
42. Regulation of lactate production through p53/ β -enolase axis contributes to statin-associated muscle symptoms. *EBioMedicine*, 2019, doi: 10.1016/j.ebiom.2019.06.003
43. QHMEM, a Quinazolinone Compound, Inhibits Proliferation and Induces Apoptosis in Human Colon Cancer HCT116 Cells. *Latin American Journal of Pharmacy*, 2019, 38(4):663-667
44. 腦膠質瘤中異檸檬酸脫氫酶突變及其抑制劑研究進展. *中國藥學雜誌*, 2019. 54(03): 165-169.
45. Integrative omics analysis of p53-dependent regulation of metabolism. *FEBS Letters*, 2018, 592(3):380-393
46. APTM, a Thiophene Heterocyclic Compound, Inhibits Human Colon Cancer HCT116 Cell Proliferation Through p53-Dependent Induction of Apoptosis. *DNA and Cell Biology*, 2018. 37(2): 70-77.
47. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells in vitro. *Scientific Reports*, 2017, doi:10.1038/s41598-017-02222-0
48. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha. *Pharmacological Research*, 2016, 111:849-858
49. Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan). *Chinese Medicine*, 2016, 11:43-58

50. In Vitro Anticancer Activity of a Nonpolar Fraction from *Gynostemma pentaphyllum* (Thunb.) Makino. *Evidence-Based Complementary and Alternative Medicine*, 2016, doi: 10.1155/2016/6308649
51. Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. *Scientific Reports*, 2015, 5: 18789
52. Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction. *Free Radical Biology and Medicine*, 2014, 73: 270-277
53. Increased Oxidative Metabolism in the Li–Fraumeni Syndrome. *New England Journal of Medicine*, 2013, 368(11):1027-1032
54. Ambient Oxygen as a Tumor Promoter. *PLoS ONE*, 2011, 6(5): e19785
55. Mitochondrial Respiration Protects Against Oxygen-associated DNA Damage. *Nature Communications*, 2010, 1:5 doi: 10.1038/ncomms1003
56. A pivotal role for p53: balancing aerobic respiration and glycolysis. *J Bioenerg Biomembr*, 2007, 39(3): 243-246
57. Expression and purification of a putative tumor suppressor gene PP5715 in E.coli with growth inhibition to hepatocellular carcinoma cells. *Protein and Peptide Letters*, 2006, 13: 41-45
58. Construction, expression, purification and antiviral activity of fusing interferon-BLA (IFN-BLA). *Hereditas* (Beijing), 2005, 27 : 451-456
59. 頭狀鏈黴菌原生質體的製備及其誘變. 中國藥科大學學報, 2002(01): 64-67.
60. 頭狀鏈黴菌中絲裂黴素C抗性基因mcrAB的克隆及其作用研究. 中國抗生素雜誌, 2002(12): 748-752.